Log in to search using one of your social media accounts:

 

Effect of rosuvastatin on fasting and postprandial endothelial biomarker levels and microvascular reactivity in patients with type 2 diabetes and dyslipidemia: a preliminary report

The cardiovascular benefits of statins have been proven, but their effect on circulation in small vessels has not been examined fully. We investigated the effect of 20  mg rosuvastatin on biomarkers, including ...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Original investigation Source Type: research

Related Links:

Type 2 diabetes is associated with elevated levels of triglycerides and small, dense low-density lipoprotein particles, in addition to low levels of high-density lipoprotein cholesterol. Clinical trials have demonstrated the clear cardiovascular benefit of use of statin therapy in patients with diabetes. Additional lipid-modifying agents are typically guided by the presence of additional lipid abnormalities. The optimal use of existing lipid agents and the potential for novel therapies in patients with diabetes is reviewed.
Source: Cardiology Clinics - Category: Cardiology Authors: Source Type: research
Authors: Chen PH, Wang JS, Lin SY, Li CH, Wang CY, Hu JY, Fu CP, Tsai YT, Lee AT, Chen YW, Li YH, Lee CL Abstract OBJECTIVE: To investigate the effects of statins on all-cause mortality risk at different low-density lipoprotein cholesterol (LDL-C) levels and to compare the mortality risk between statin users and nonusers with identical LDL-C levels in a type 2 diabetes cohort. METHODS: In total, 10,582 outpatients aged ≥ 18 years with type 2 diabetes mellitus (T2DM) between 2009 and 2012 were enrolled in this retrospective cohort study in central Taiwan. All-cause mortality events were followed up until the ...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Abstract Our aim was to review the data from the National Pregnancy in Diabetes (NPID) audit, and to identify the challenges and opportunities for improving pregnancy outcomes in women with diabetes. We reviewed three years of NPID data and relevant diabetes and obstetric literature, and found that there has been little change in pregnancy preparation or outcomes over the past 3 years, with substantial clinic‐to clinic variations in care. Women with Type 2 diabetes remain less likely to take 5 mg preconception folic acid (22.8% vs. 41.8%; P 
Source: Diabetic Medicine - Category: Endocrinology Authors: Tags: Invited Review Source Type: research
DiscussionIf anagliptin were to be shown to reduce LDL-C in patients with type 2 diabetes and atherosclerotic vascular lesions despite pre-existing statin treatment, more intensive cholesterol management would be appropriate.Trial RegistrationClinicaltrials.gov NCT02330406
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
Let’s take back control over personal health. Share this to expose healthcare for the corrupt enterprise it is. Imagine that you receive a letter in the mail stating “In order to retain your right to freedom of speech, you will be billed $10,000 per year every year for the rest of your life.” You would be—-understandably-—outraged. Freedom of speech in America is precious, something Americans have waged wars to defend, something we now view as a basic right, no financial price required to maintain it. It should be free and available to everyone regardless of religion, color, political leanin...
Source: Wheat Belly Blog - Category: Cardiology Authors: Tags: Undoctored Wheat Belly Lifestyle diy health Dr. Davis grain-free healthcare Source Type: blogs
CONCLUSIONS: No evidence of an association between the use of metformin or statins and the incidence of ovarian cancer in patients with T2D was found. This article is protected by copyright. All rights reserved. PMID: 29412502 [PubMed - as supplied by publisher]
Source: BJOG : An International Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Tags: BJOG Source Type: research
This study aimed to determine prognostic survival factors for diabetic patients with resected non‐small cell lung cancer. Patients and MethodsBetween January 2005 and December 2013, 301 patients with type 2 diabetes mellitus who underwent curative resection for non‐small cell lung cancer were identified and reviewed retrospectively. ResultsThe median follow‐up period was 48 months. In multivariate analysis for lung cancer‐specific survival, older age, forced expiratory volume in 1 s (FEV1)
Source: Journal of Surgical Oncology - Category: Cancer & Oncology Authors: Tags: RESEARCH ARTICLE Source Type: research
ConclusionsNo evidence of an association between the use of metformin or statins and the incidence of ovarian cancer in patients with T2D was found.This article is protected by copyright. All rights reserved.
Source: BJOG: An International Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Tags: Main Research Article Source Type: research
Abstract AimsIndividuals with type 2 diabetes (T2DM) and mixed dyslipidaemia represent a high‐risk and difficult‐to‐treat population. ODYSSEY DM‐DYSLIPIDEMIA (NCT02642159) compared alirocumab, a proprotein convertase subtilisin‐kexin type 9 inhibitor, with usual care (UC) in individuals with T2DM and mixed dyslipidaemia not optimally managed by maximally‐tolerated statins. Materials and MethodsUC options (no additional lipid‐lowering therapy; fenofibrate; ezetimibe; omega‐3 fatty acid; nicotinic acid) were selected prior to stratified randomization to open‐label alirocumab 75 mg every 2 weeks (Q2W; with i...
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Abstract Peripheral artery disease (PAD) is characterized by increased cardiovascular (CV) risk, limb morbidity and all-cause mortality. According to the current guidelines (2016) of the American Heart Association/American College of Cardiology on the management of PAD patients, statin therapy is recommended for PAD patients in order to treat dyslipidemia and reduce CV risk. The present narrative review discusses the use of statins and other lipid-lowering drugs such as ezetimibe, fibrates, niacin, anacetrapib and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in PAD patients in terms of both CV ...
Source: Current Opinion in Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Opin Pharmacol Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Crestor | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Rosuvastatin | Statin Therapy